Prof. L. de Haan PhD

All Publications

Curriculum Vitae Lieuwe de Haan, Version 30-6-2010

MD PhD, Lieuwe de Haan
Male, Married, 3 children
26 April 1960, Assen

Master’s

Vrije Universiteit Amsterdam
August 1986 M.D. (Cum Laude),

PhD

University of Amsterdam
March 2002 Ph.D.
Supervisor: Prof Dr. DH Linszen, Prof Dr. BPR Gersons
Title thesis: Patients’ perspectives; Subjective experiences and attitudes of patients with recent onset schizophrenia

Work experience since graduating

1986-1991 Resident in Psychiatry, PCA Valeriuskliniek, Amsterdam (fixed term, full time)
1991-1992 Resident in Child and Adolescent Psychiatry, Kinderpsychiatrisch Centrum Curium, Oegstgeest (fixed term, full time)
1992-1993 Resident in Social Psychiatry Centrale Riagg Dienst Amsterdam (fixed term, full time)
1993- Consultant Psychiatrist, Senior Lecturer, Zorglijn Vroege Psychose, Divisie Psychiatrie, AMC (tenured, full time)

Brief summary of research over last five years

In the past 5 years L. de Haan focused on subjective experiences on antipsychotic treatment of patients with schizophrenia. Epidemiological and biological factors associated with subjective response to antipsychotic medication were studied. Two randomized controlled trials with subjective response to antipsychotic medication as primary outcome measure were conducted.
Since 2003 L. de Haan is site coordinator in a national multicentre project, since 2010 member of the steering committee: Genetic Risk and Outcome of Psychosis (GROUP). Purpose of this project is to investigate the vulnerability and protective factors (and their interactions) for the development of a psychotic disorder, and the variation in the course of the disorder. A population-based cohort of patients with a recently developed psychotic disorder (n=1000), subjects at risk (brothers/sisters, n=1000), parents (n=1000) and healthy volunteers (n=700) is established. Subjective response to antipsychotic medication is the focus of an add-on study of the GROUP study. Obsessive-compulsive symptoms in patients with psychotic disorders is another focus of the research of L. de Haan. He is co-investigator in a multi-national EU funded study on Gene-Environment interactions in Schizophrenia.
Fundamental and clinical aspects of psychopharmacological influences on craving for cannabis in patients with schizophrenia is a major theme for recently started research projects.

International activities

- Mentor of the Young Investigator Program of the International Congress on Schizophrenia Research
- Expert in MATRA III project (Developing modules social psychiatry in the Czech Republic, project from the Ministry of External Affairs) 2003.

- Reviewer international: Plos one, The Lancet, Archives of General Psychiatry, American Journal of Psychiatry, Schizophrenia Bulletin, Neuropsychopharmacology, Journal of clinical psychiatry, Schizophrenia Research, Psychiatry Research, Psychopharmacology, Clinical Neuropharmacology, PPP Healthcare Medical Trust, Pharmacopsychiatry, International Journal of Psychiatry in Clinical Practice
- Member of the Advisory Board of Psychiatrics

- International invitations:
Five year course of Obsessive compulsive symptoms in first episode schizophrenia. International congress on schizophrenia research, Florence, 15 april 2010
Dopamine and the Subjective experience of patients with Schizophrenia – International congress on schizophrenia research, Colorado Springs, 23 june 2008
Dopamine, Reward and the Subjective experience of patients with Schizophrenia – Concepts and Imaging, CINP, Chicago, 9 – 14 july 2006
Neuroleptic dysphoria - stage of illness and type of medication - International congress on schizophrenia research, Colorado Springs, 29 maart - 2 april 2003
Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia European Regional Congress of WFSBP, Copenhagen, Denmark, 13 – 16 June 2002
How is optimal dosage to be determined? Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized on olanzapine or risperidone - 10th Biennal Winterworkshop on schizophrenia, Davos, 5-11 Februari 2000
Improvement of social functioning after admission of patients with recent onset schizophrenic disorders - Vth Congress World Association for Psychosocial Rehabilitation, Rotterdam, April 23 1996
Duration of untreated psychosis and prognosis - First episode in schizophrenia congress, Amsterdam, 28 November 1996
Delay in intensive psychosocial intervention - First episode in schizophrenia congress, Amsterdam, 29 November 1996

- International collaborations:
Germany, Department of Psychiatry and Psychotherapy, University of Hamburg, Hamburg, Naber D
Canada, Department of Psychiatry, University of Toronto, Kapur S
England, Institute of Psychiatry, London, Kapur S
Canada, McMaster University, Hamilton, Voruganti L, Szechtman H
Canada, Eli Lilly Scarborough, Karagianis JL, MD

Other academic activities
Since 2003 L. de Haan is member of the editorial board of “Tijdschrift voor Psychiatrie” since 2006 citated on medline.
Since 2003 L. de Haan is site-coordinator of the Genetic Risk and Outcome of Psychosis study (GROUP).
Since 2006 L. de Haan is chairman of the site-coordinators of the GROUP study and member of the steering committee of GROUP.
From 2005 – 2009 L. de Haan was chairman of the “Commissie Wetenschap van de Nederlandse Vereniging voor Psychiatrie”.

Involved in the following current PhD projects
1. Mw. L van Nimwegen (AMC) Subjective well-being and craving for cannabis in schizophrenia. Thesis defence 15 October 2008
2. J.M. van Beveren (Erasmus MC) Schizophrenia-associated neural growth factors. Thesis defence: 18 may 2010
3. B. Peters (AMC) White Matters: Diffusion Tensor Imaging in Schizophrenia, Expected date of thesis defence: 7 september 2010
4. E. Barkhof (AMC) Motivational interviewing for non compliance in schizophrenia, Expected date of thesis defence: 2011
5. M.A.M. Boerma (InGeest) Women and recent onset psychotic disorders: estrogens, cognitive functioning, menarche, Expected date of thesis defence: 2012
6. S. Vothknecht (Arkin) Subjective experiences of patients with recent onset psychosis related to antipsychotic medication, Expected date of thesis defence: 2012
7. M. Swets (Arkin) Obsessive-compulsive symptoms in patients with recent-onset schizophrenia and related disorders, Expected date of thesis defence: 2012
8. Mw. W. Hoen (Arkin) Metabolism of fatty acids in patients with recent onset schizophrenia and related disorders, Expected date of thesis defence: 2012
9. Mw. M. C.Klaassen (Rivierduinen) Depressive symptoms in the early course of schizophrenia, Expected date of thesis defence: 2012
10. P.D. Meesters (InGeest) Schizofrenie op oudere leeftijd (SOUL), Expected date of thesis defence: 2011
11. Marise Machielsen (AMC). Het effect van risperidon en clozapine op craving pathways. Een gerandomiseerde dubbel-blind fMRI onderzoek. Expected date of thesis defence: 2011
12. Albertine Scheltema Beduin (AMC). Het effect van clozapine en olanzapine op middelengebruik bij patiënten met een schizofrene stoornis en verslaving. Randomized Olanzapine Clozapine Key Study on Addiction in the Netherlands [ROCKSAN] Expected date of thesis defence: 2012
13. Bouke Sterk (AMC). Tijdige onderkenning psychose en duur onbehandelde psychose Expected date of thesis defence: 2011
14. Sara Dragt (AMC). Cognitieve gedragstherapie bij patiënten met een hoog risico op psychose
Expected date of thesis defence: 2011
15. Oswald Bloemen (AMC). Dopaminerge neurotransmissie bij patiënten met een hoog risico op psychose Expected date of thesis defence: 2011
16. Erik Boot. Dopaminerge neurotransmissie bij patiënten met het Velo Cardio Faciaal Syndroom. Expected date of thesis defence: 2010.
17. Julia Meijer (AMC). Reuk en schizofrenie Expected date of thesis defence: 2012
18. Nikie Korver (AMC). Hechting en psychose Expected date of thesis defence: 2012
19. Eva Velthorst (AMC) Predictie van Transitie naar Psychose
20. Anita Wessels (Dimens) Sport en psychose
21. Mirjam van Tricht (AMC) Neurofysiologische afwijkingen bij schizofrenie
22. N. Dekker (AMC) Cannabis and schizophrenia, patients and siblings, Expected date of thesis defence: 2011
23. Hiske Becker (AMC). Neuropsychologie in de voorspelling van psychose. Expected date of thesis defence: 2011
24. Renate van der Valk (AMC). Trait anxiety and psychosis

Member of the supervising committee
Research in Mentrum on forced psychiatric treatment L. van der Post.
Trimbos research on nurse interventions at suicide: Abandon suicide. E Broers, J van Weeghel.

Reviewer national: Tijdschrift voor Psychiatrie, Maandblad Geestelijke Volksgezondheid, Nederlands Tijdschrift voor Geneeskunde

Organisation:
Chairman Voorjaarscongres van de Nederlandse Vereniging voor Psychiatrie, 2008 Amsterdam
Theme: Preventie (congres 3 days, 2800 participants)
Chairman Voorjaarscongres van de Nederlandse Vereniging voor Psychiatrie, 2007 Maastricht
Theme: Psychiatrie in Europa (congres 3 days, 2500 participants)
Chairman Voorzitter Voorjaarscongres van de Nederlandse Vereniging voor Psychiatrie, 2006 Groningen Theme: Ontwikkeling en levensloop (congres 3 days, 2300 participants)
Chairman Voorjaarscongres van de Nederlandse Vereniging voor Psychiatrie, 2005 Den Haag
Theme: Education Permanente (congres 3 days, 2300 participants)
Chairman: Cursus voor huisartsen Schizofrenie: diagnostiek en behandeling, Champery, 18 jamuari 2002
Coordinator Blok Psychotische stoornissen, Onderwijs aan arts-assistenten in opleiding tot psychiater consortium Noord-Holland, sinds 2000
Coordinator co-schappen Psychiatrie AMC, sinds 1997
Chairman Cursus voor huisartsen,Psychotische stoornissen, Clermont-Ferrand, 4-8 juni 1997
Chairman Symposium voor huisartsen en jeugdartsen,Vroeg herkenning van schizofrenie, Amsterdam, 28 November 1996

Local collaborations:
Department of Nuclear Medicine, AMC, Booij J
Laboratorium Genetische Metabole Ziekten, AMC, Duran R, Wanders R
Department of Radiology, Majoie CBLM, Den Heeten GJ,

National collaborations:
UMC Utrecht, Kahn RS, Cahn W,
UMC Groningen, Wiersma D, Bruggeman R
UMC Maastricht, Van Os, Germeys I
VU Krabbendam L
Erasmus MC, Hengeveld M, Van Beveren N
GGZ Noord Holland Noord, Monden M, Wisman H, Keet R
GGZ Arkin Swets M, Vothknecht S, Schoevers R, Van der Post, Dekker J, Hoen W
GGZ In Geest, Boerma M, Meesters PD, Beekman ATF
GGZ Rivierduinen, Klaassen R
Altrecht, Kleijweg MM
Antonius ziekenhuis Nieuwegein, Lavalaye J
 

Scholarships prizes, and grants

(in collaboration with others or alone)
- Award of the British Medical Association Mental Health Book of Year 1st prize, Marihuana and Madness. D. Castle, R. Murray, editors, Cambridge University Press, Cambridge, 2005, Cannabis abuse and the course of schizophrenia, Linszen DH, Peters B, De Haan L, Pag. 119-126
- Nominated for the best article Tijdschrift voor Psychiatrie, 2006: Resterende neuropsychologische stoornissen, structurele en functionele hersenafwijkingen na langdurig cannabisgebruik, Weeda MR, Peters BD, De Haan L , Linszen DH, Tijdschrift voor Psychiatrie, 2006, 48, 185-193
- Award for the best article Tijdschrift voor Psychiatrie, 2004: Genetisch onderzoek bij schizofrenie: een overzicht. Figee M, Van Amelsvoort T, De Haan L, Linszen DH, Tijdschrift voor Psychiatrie, 2004, 46, 15-26
- Promovendi Primeur Award 2002, De Haan L Beste Presentatie
- Janssen Cilag Schizofrenie Prijs 2002 De Haan L € 10.000
- Aanmoedigingsprijs Ypsilon De Haan L 1994

L de Haan has received (in collaboration with others) the following grants, total amount is mentioned:

- ‘Early detection of psychosis: the efficacy of an early detection program in Amsterdam’
Linszen DH, Van Amelsvoort TA, Becker HE, Birchwood M, Dingemans PM, De Haan L [Principal Investigator], Lester H, Nieman D, Van der Fliert R, € 468.719 ZonMW

- EU European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI), Large Scale Integrating project HEALTH-2009-2.2.1-2: Identifying genetic and environmental interactions in schizophrenia.
Principal Investigator Van Os J.
De Haan L Principal Investigator AMC part
(a.) Projectleader Workpackage Training. AMC part: € 526.286
(b.) Projectmember of workpackage Functional Enviromics € 379.628
(c.) Projectmember Workpackage GxE Prodrome € 115.286
Total AMC part: € 1.021.200

- Genetic Risk and Outcome of Psychosis (GROUP), Project team members: Linszen DH, De Haan L, Kahn RS, Cahn W, Wiersma D, Bruggeman R, Van Os, Krabbendam L, total: € 5.088.420, AMC part: € 1.272.105, ZonMW

- Unrestricted grant pharmaceutical companies for the GROUP project (Eli Lilly Nederland, Dr. Paul Janssen Stichting, AstraZeneca, Bristol Myers Squibb), Project team members: Linszen DH, De Haan L, Kahn RS, Cahn W, Wiersma D, Bruggeman R, Van Os, Krabbendam L, total: € 800.000, AMC part: € 200.000

- Mental illness, genomics and society, Project team members: Meijman FJ, VU University Medical Centre/Metamedica, Kahn RS, Linszen DH, Cahn W, De Haan L, Wiersma D, Bruggeman R, Van Os, Krabbendam L Cornel M, Van Tilburg W, VU University, € 160.000 , AMC part: € 40.000, Funding Centre for Society and Genomics

- Subjective well-being, craving for cannabis and compliance or medication switch in a randomized double blind study with olanzapine or risperidone, De Haan L [Principal Investigator], Project team members: Linszen DH, Van den Brink W, € 180.000

- Placebo and active comparator trial of olanzapine zydis pills used sublingually, P.I.: Karagianis J (Canada) De Haan L [P.I. The Netherlands]: total € 380.000 AMC part: € 20.000

- MIGROUP, samen met, J.P. Selten, R. Schoevers, P.I.: Selten JP Project team members: Havenaar J, Schoevers R, De Haan L, € 50.100

- Effect of different antipsychotic medications on craving and craving related brain activity in patients with schizophrenia and cannabis abuse or dependence:a randomized controlled study comparing clozapine and risperidone De Haan L [Principal Investigator], Linszen DH, Van den Brink W, Veltman D. ZonMW € 353.972

- Multi-Center Studie Clozapine vs olanzapine intervention in patients with schizophrenia and co-morbid substance use, a multi-centre double blind randomized trial (aanvraag 637) , Linszen DH, De Haan L [Principal Investigator], Van den Brink W, Schulte R. ZonMW € 494,056

5.0. In Press

Three year course of clinical symptomatology in young people at ultra high risk for transition to psychosis
Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, Linszen DH, De Haan L
Acta Psychiatrica Scandinavica in press

Disability in patients clinically at high risk for a psychosis
Velthorst E, Nieman D, Linszen D, Becker H, De Haan L, Dingemans P, Birchwood M, Patterson P, Salokangas R, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Schultze-Lutter F, Klosterkötter J, Ruhrmann S
British Journal of Psychiatry in press

Schizophrenia in later life: one-year prevalence and distribution of age at onset and sex in a catchment area in Amsterdam
Meesters PD, De Haan L, Comijs HC, Stek ML, Eikelenboom P, Smit JP,
Beekman ATF
The American Journal of geriatric psychiatry in press

GWA study data-mining and independent replication identify cardiomyopathy associated 5 (CMYA5) as a risk gene for schizophrenia
Chen X, Lee G, Maher BS, Fanous AH, Chen J, Zhao Z, Guo A, van den Oord E, Sullivan PF, Shi X, Levinso DF, Gejman P, Sanders A, Duan J, Owen MJ, Craddock NJ, C O’Donovan M, Blackman J, Lewis D, Qin W, Schwab S, Wildenauer D, Chowdari K, Nimgaonkar V, Straub R, Weinberger DR, O’Neill A, Walsh D, Darvasi A, Lencz T, Malhotra AK, Rujescu D, Giegling I, Werge T, Hansen T, Ingason A, Nöthen MM, Rietschel M, Cichon S, Djurovic S, Andreassen O, Cantor R, Ophoff R, Corvin A, Morris DW, Gill M, Pato CN, Pato MT, Macedo A, Gurling H, McQuillin A, Pimm J, Hultman C, Lichtenstein P, Sklar P, Purcell S, Scolnick E, St Clai Dr, Blackwood D, the GROUP investigators: Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I, the International Schizophrenia Consortium, Kendler KS

Three year course of clinical symptomatology in young people at ultra high risk for transition to psychosis
Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, Linszen DH, De Haan L
In press Acta Psychiatrica Scandinavica

Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode
Van Tricht MJ, Nieman DH, Koelman JHTM, Van der Meer J, Bour LJ, De Haan L, Linszen D
Biological Psychiatry, in press

Emotional Experience and Estimates of D2 Receptor Occupancy in Psychotic Patients Treated with Haloperidol, Risperidone, or Olanzapine: an Experience Sampling Study
Lataster J, van Os J, De Haan L, Thewissen V, Bak M, Lataster T, Lardinois M, Delespaul P, Myin-Germeys, I
The Journal of Clincial Psychiatry, in press

Cannabis use in patients with a first psychotic episode and subjects at Ultra High Risk of psychosis: impact on psychotic- and pre-psychotic symptoms.
Machielsen M, Van der Sluis S, De Haan L
Australian and New Zealand Journal of Psychiatry, in press

Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission
Machielsen M, De Haan L
Psychopharmacol Bull. 2010 In press

Neurocognitive functioning before and after a First psychotic episode: Does psychosis result in cognitive deterioration?
Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, De Haan L, van Amelsvoort A, Linszen DH. Psychological Medicine, in press.

Social functioning among older community-dwelling patients with schizophrenia: a review
Meesters PD, Stek M, Comijs HC, De Haan L , Patterson TL, Eikelenboom P, Beekman ATF
The American Journal of geriatric psychiatry in press

Factors associated with weight change during 16 weeks of therapy with sublingual orally disintegrating olanzapine or standard olanzapine tablets: results from exploratory analyses of a randomized, double-blind, clinical trial
Karagianis J, Landry J, Hoffmann VP, Grossman L, De Haan L, Maguire G, Milev R, Holt S
International Journal of Clinical Practice in press

5.1. Publications

- International (refereed) publications

163. The association between social anhedonia, withdrawal and psychotic experiences in general and high-risk populations.
Velthorst E, Meijer C; G.R.O.U.P. Investigators.
Schizophrenia Research 2012 Jul;138(2-3):290-4. Epub 2012 Apr 6

162. The Strauss and Carpenter Prognostic Scale in subjects clinically at high risk of psychosis.
Nieman DH, Velthorst E, Becker HE, de Haan L, Dingemans PM, Linszen DH, Birchwood M, Patterson P, Salokangas RK, Heinimaa M, Heinz A, Juckel G, von Reventlow HG, Morrison A, Schultze-Lutter F, Klosterkötter J, Ruhrmann S; on behalf of the EPOS group.
Acta Psychiatrica Scandinavica 2012 Jul 7. doi: 10.1111/j.1600-0447.2012.01899.x. [Epub ahead of print]

161. Childhood bullying and the association with psychosis in non-clinical and clinical samples: a review and meta-analysis.
van Dam DS, van der Ven E, Velthorst E, Selten JP, Morgan C, de Haan L.
Psychological Medicine 2012 Mar 9:1-12. [Epub ahead of print]

160. Age at onset of non-affective psychosis in relation to cannabis use, other drug use and gender
Dekker N, Meijer J, Koeter M, van den Brink W, van Beveren N; GROUP Investigators, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, de Haan L, Krabbendam L, Myin-Germeys I.
Psychological Medicine 2012, 42, 1903-1911

159. Social Cognitive Impairments and Psychotic Symptoms: What is the Nature of Their Association?
Fett AK, Maat A; GROUP Investigators.
Schizophr Bull. 2011 Jun 22. [Epub ahead of print]

158. Social cognition and quality of life in schizophrenia.
Maat A, Fett AK, Derks E; GROUP Investigators.
Schizophrenia Research 2012 Mar 7. [Epub ahead of print]

157. Intermediate Phenotype Analysis of Patients, Unaffected Siblings, and Healthy Controls Identifies VMAT2 as a Candidate Gene for Psychotic Disorder and Neurocognition.
Simons CJ, van Winkel R; GROUP investigators.
Schizophrenia Bull. 2012 Apr 24.

156. No evidence for familial covariation of neurocognition and negative symptoms in psychotic disorders.
Lataster T, Shazad A, Henquet C, GROUP Investigators.
Schizophrenia Research 2012

155. Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective
psychotic illness and their unaffected siblings.
Meijer JH, Dekker N, Koeter MW, Quee PJ, van Beveren NJM, Meijer CM; GROUP Investigators.
Psychological Medicine 2012, 42, 705–716. f Cambridge University Press 2011

154. Cognitive impairment in late life schizophrenia and bipolar I disorder.
Meesters P, Schouws S, Stek M, de Haan L, Smit J, Eikelenboom P, Beekman AJ, Comijs H.
International Journal Geriatric Psychiatry, 2012.

153. Marked Reduction of AKT1 Expression and Deregulation of AKT1-Associated Pathways in Peripheral Blood Mononuclear Cells of Schizophrenia Patients.
van Beveren NJM, Buitendijk GHS, Swagemakers S, Krab LC, Röder C, de Haan L, van der Spek P, Elgersma P.
PLoS ONE, 2012 February 7, (2).

152. Cognitive alterations in patients with non-affective psychotic disorder and their unaffected siblings and parents.
Meijer J, Simons CJ, Quee PJ, Verweij K; GROUP Investigators.
Acta Psychiatrica Scandinavica 2012 Jan;125(1):66-76.

151. Schizophrenia Spectrum Disorders in Later Life: Prevalence and Distribution of Age at Onset and Sex in a Dutch Catchment Area.
Paul D. Meesters, M.D., Lieuwe De Haan, M.D., Ph.D., Hannie C. Comijs, Ph.D., Max L. Stek, M.D., Ph.D., Maureen M.J. Smeets-Janssen, M.D., Ph.D., Marjan R. Weeda, M.D., Piet Eikelenboom, M.D., Ph.D.,
Johannes H. Smit, Ph.D., Aartjan T.F. Beekman, M.D., Ph.D.
American Journal Geriatric Psychiatry 20:1, January 2012

150. Daily cortisol, stress reactivity and psychotic experiences in individuals at above average genetic
risk for psychosis.
Collip D, Nicolson NA, Lardinois M, T. Lataster, van Os J, Myin-Germeys I; GROUP Investigators.
Psychological Medicine (2011), 41, 2305–2315. f Cambridge University Press 2011

149. The validity of the DSM-IV diagnostic classification system of non-affective psychoses.
Korver-Nieberg N, Quee PJ, Boos HB, Simons CJ; GROUP Investigators.
The Australian and New Zealand journal of psychiatry. 2011 Dec;45(12):1061-8. Epub 2011 Oct 25. PubMed PMID: 22026404.

148. Motivational interviewing and interaction skills training for parents to change cannabis use in young adults with recent-onset schizophrenia: a randomized controlled trial.
Smeerdijk M, Keet R, Dekker N, van Raaij B, Krikke M, Koeter M, De Haan L, Barrowclough C, Schippers G, Linszen D.
Psychological Medicine, 2011 Dec 8:1-10. [Epub ahead of print]

147. Correction: proton magnetic resonance spectroscopy in 22q11 deletion syndrome.
Da Silva Alves F, Boot E, Schmitz N, Nederveen A, Vorstman J, Lavini C, Pouwels P, De Haan L, Linszen D, van Amelsvoort T.
PLOS ONE 2011;ahead of print[ PubMed ]

146. White matter abnormalities in adults with 22q11 deletion syndrome with and without schizophrenia.
Da Silva Alves F, Schmitz N, Bloemen O, van der Meer J, Meijer J, Boot E, Nederveen A, De Haan L, Linszen D, van Amelsvoort T.
Schizophrenia Research 2011;132 (1):75-83[ PubMed ]

145. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.
Van Winkel R, van Beveren NJ, Simons C; Genetic Risk and Outcome of Psychosis (GROUP) Investigators.
Neuropsychopharmacology. 2011 Nov;36(12):2529-37. doi: 10.1038/npp.2011.141. Epub 2011 Jul 20.

144. Ultra high-risk state for psychosis and non-transition: a systematic review.
Simon AE, Velthorst E, Nieman DH, Linszen D, Umbricht D, De Haan L.
Schizophrenia Research 2011 Oct;132(1):8-17. Epub 2011 Jul 23.

143. Genome-wide association study identifies five new schizophrenia loci.
Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, De Hert M, Jönsson EG, Bitter I, Pietiläinen OP, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, De Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshere M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jürgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, Lieberman JA, Linszen DH, Lönnqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nöthen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Orntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quested D, Quinn EM, Rasmussen HB, Réthelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CC, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV; Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium.
Nature Genetics 2011 Sep 18;43(10):969-76. doi: 10.1038/ng.940.

142. Factor analysis of the scale of prodromal symptoms: differentiating between negative and depression symptoms
Klaassen RM, Velthorst E, Nieman DH, De Haan L, Becker HE, Dingemans PM, van de Fliert JR, van der Gaag M, Linszen DH.
Psychopathology. 2011;44(6):379-85. doi: 10.1159/000325169. Epub 2011 Aug 17.

141. Ethnicity and baseline symptomatology in patients with an At Risk Mental State for psychosis.
Velthorst E, Nieman DH, Veling W, Klaassen RM, Dragt S, Rietdijk J, Ising H, Wunderink L, Linszen DH, De Haan L, van der Gaag M.
Psychol Med. 2011 Aug 11:1-10. [Epub ahead of print]

140. Hippocampal glutamate levels and striatal dopamine D(2/3) receptor occupancy in subjects at ultra high risk of psychosis.
Bloemen OJ, Gleich T, de Koning MB, da Silva Alvis F, De Haan L, Linszen DH, Booij J, van Amelsvoort TA.
Biological Psychiatry. 2011 Jul 1;70(1):e1-2; author reply e3. Epub 2011 Apr 8.

139. Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Steinberg S, de Jong S; Irish Schizophrenia Genomics Consortium, Andreassen OA, Werge T, Børglum AD, Mors O, Mortensen PB, Gustafsson O, Costas J, Pietiläinen OP, Demontis D, Papiol S, Huttenlocher J, Mattheisen M, Breuer R, Vassos E, Giegling I, Fraser G, Walker N, Tuulio-Henriksson A, Suvisaari J, Lönnqvist J, Paunio T, Agartz I, Melle I, Djurovic S, Strengman E; GROUP, Jürgens G, Glenthøj B, Terenius L, Hougaard DM, Ørntoft T, Wiuf C, Didriksen M, Hollegaard MV, Nordentoft M, van Winkel R, Kenis G, Abramova L, Kaleda V, Arrojo M, Sanjuán J, Arango C, Sperling S, Rossner M, Ribolsi M, Magni V, Siracusano A, Christiansen C, Kiemeney LA, Veldink J, van den Berg L, Ingason A, Muglia P, Murray R, Nöthen MM, Sigurdsson E, Petursson H, Thorsteinsdottir U, Kong A, Rubino IA, De Hert M, Réthelyi JM, Bitter I, Jönsson EG, Golimbet V, Carracedo A, Ehrenreich H, Craddock N, Owen MJ, O'Donovan MC; Wellcome Trust Case Control Consortium 2, Ruggeri M, Tosato S, Peltonen L, Ophoff RA, Collier DA, St Clair D, Rietschel M, Cichon S, Stefansson H, Rujescu D, Stefansson K.
Human Molecular Genetics. 2011 Oct 15;20(20):4076-81. Epub 2011 Jul 26.

138. The 5-Year Course of Obsessive-Compulsive Symptoms and Obsessive-Compulsive Disorder in First-Episode Schizophrenia and Related Disorders.
De Haan L, Sterk B, Wouters L, Linszen DH.
Schizophrenia Bulletin. 2011 Jul 28. [Epub ahead of print]

137. Social disability at admission for a first psychosis does not predict clinical outcome at 5-year follow-up.
Velthorst E, Nieman DH, Meijer C, Linszen D, De Haan L.
The Journal of Nervous and Mental Disease 2011 Jul;199(7):510-2.

136. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.
Machielsen M, Scheltema Beduin A, Dekker N, Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I.
Journal of Psychopharmacology 2011 Jul 18. [Epub ahead of print]

135. Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe.
Rietschel M, Mattheisen M, Degenhardt F; GROUP Investigators; Genetic Risk and Outcome in Psychosis (GROUP Investigators), Kahn RS, Linszen DH, Os JV, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I, Mühleisen TW, Kirsch P, Esslinger C, Herms S, Demontis D, Steffens M, Strohmaier J, Haenisch B, Breuer R, Czerski PM, Giegling I, Strengman E, Schmael C, Mors O, Mortensen PB, Hougaard DM, Orntoft T, Kapelski P, Priebe L, Basmanav FB, Forstner AJ, Hoffmann P, Meier S, Nikitopoulos J, Moebus S, Alexander M, Mössner R, Wichmann HE, Schreiber S, Rivandeneira F, Hofman A, Uitterlinden AG, Wienker TF, Schumacher J, Hauser J, Maier W, Cantor RM, Erk S, Schulze TG; SGENE-plus Consortium; (Only those persons responsible for the samples of Replication 2 are listed), Stefansson H, Steinberg S, Gustafsson O, Sigurdsson E, Petursson H, Kong A, Stefansson K, Pietiläinen OP, Tuulio-Henriksson A, Paunio T, Lonnqvist J, Suvisaari J, Peltonen L, Ruggeri M, Tosato S, Walshe M, Murray R, Collier DA, Clair DS, Hansen T, Ingason A, Jakobsen KD, Duong L, Werge T, Melle I, Andreassen OA, Djurovic S, Bitter I, Réthelyi JM, Abramova L, Kaleda V, Golimbet V, Jönsson EG, Terenius L, Agartz I, Winkel RV, Kenis G, Hert MD, Veldink J, Wiuf C, Didriksen M, Craddock N, Owen MJ, O'Donovan MC, Børglum AD, Rujescu D, Walter H, Meyer-Lindenberg A, Nöthen MM, Ophoff RA, Cichon S.
Molecular Psychiatry. 2011 Jul 12. doi: 10.1038/mp.2011.80. [Epub ahead of print]

134. Auditory ERP components before and after transition to a first psychotic episode.
Van Tricht MJ, Nieman DH, Koelman JH, Bour LJ, van der Meer JN, van Amelsvoort TA, Linszen DH, De Haan L.
Biological Psychology 2011 Jul;87(3):350-7. Epub 2011 Apr 30.

133. Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic
illness. Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, Möller HJ, McQuillin A, Muglia P, Cichon S, Rietschel M, Ophoff RA, Djurovic S, Andreassen OA, Pietiläinen OP, Peltonen L, Dempster E, Collier DA, St Clair D, Rasmussen HB, Glenthøj BY, Kiemeney LA,
Franke B, Tosato S, Bonetto C, Saemundsen E, Hreidarsson SJ; Genetic Risk and Outcome of Psychosis (GROUP), Nöthen MM, Gurling H, O'Donovan MC, Owen MJ, Sigurdsson E, Petursson H, Stefansson H, Rujescu D, Stefansson K, Werge T.
The American Journal of Psychiatry, 2011 Apr;168(4):408-17. Epub 2011 Feb 15. PubMed PMID:
21324950.

132. Factor structure of the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) in a large sample of patients with schizophrenia or related disorders and comorbid obsessive-compulsive symptoms.
Boyette L, Swets M, Meijer C, Wouters L, GROUP.
Psychiatry Research 2011 Apr 30;186(2-3):409-13. Epub 2010 Aug 30.

131. Association of treatment delay, migration and urbanicity in psychosis.
Boonstra N, Sterk B, Wunderink L, Sytema S, De Haan L, Wiersma D.
European Psychiatry. 2011 Jun 24. [Epub ahead of print]

130. Social Cognitive Impairments and Psychotic Symptoms: What is the Nature of Their Association? Fett AK, Maat A; Genetic Risk and Outcome of Psychosis (GROUP).
Schizophrenia Bulletin. 2011 June 22. PubMed PMID: 21697150 [Epub ahead of print]

129. Reduced cortical thickness as an outcome of differential sensitivity to environmental risks in schizophrenia.
Habets P, Marcelis M, Gronenschild E, Drukker M, van Os J; Genetic Risk and Outcome of Psychosis (GROUP).
Biological Psychiatry. 2011 Mar 1;69(5):487-94. Epub 2010 Oct 16

128. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-A review of the past decade.
Barkhof E, Meijer CJ, de Sonneville LM, Linszen DH, De Haan L.
European Psychiatry. 2011 May 9. [Epub ahead of print]

127. Genome-Wide Analysis Shows Increased Frequency of Copy Number Variation Deletions in Dutch Schizophrenia Patients. Buizer-Voskamp JE, Muntjewerff JW; Genetic Risk and Outcome in Psychosis (GROUP) Consortium, Strengman E, Sabatti C, Stefansson H, Vorstman JA, Ophoff RA.
Biological Psychiatry. 2011 April 12. [Epub ahead of print]

126. Effects of season of birth and a common MTHFR gene variant on the risk of schizophrenia.
Muntjewerff JW, Ophoff RA, Buizer-Voskamp JE, Strengman E, den Heijer M, GROUP Consortium
European Neuropsychopharmacology (2011) 21, 300–305

125. Evidence that Familial Liability for psychosis is expressed as differential sensitivity to cannabis: an analysis of patient-sibling and sibling-control pairs. GROUP investigators.
Archives of General Psychiatry 2011 Feb; 68(2):138-47. Epub 2010 Oct 4.

124. Family-based analysis of genetic variation underlying psychosis-inducing effects
of cannabis: sibling analysis and proband follow-up. van Winkel R; Genetic Risk and Outcome of Psychosis (GROUP).
Archives of General Psychiatry, 2011 Feb;68(2):148-57. Epub 2010 Nov 1. PubMed PMID: 21041608.

123. Copy number variations of chromosome 16p13.1 region associated with schizophrenia. `
Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietiläinen OP, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, Gylfason A, Gustafsson O, Olason PI, Steinberg S, Hansen T, Jakobsen KD, Rasmussen HB, Giegling I, Möller HJ, Hartmann A, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Bramon E, Kiemeney LA, Franke B, Murray R, Vassos E, Toulopoulou T, Mühleisen TW, Tosato S, Ruggeri M, Djurovic S, Andreassen OA, Zhang Z, Werge T, Ophoff RA; GROUP Investigators, Rietschel M, Nöthen MM, Petursson H, Stefansson H, Peltonen L, Collier D, Stefansson K, St Clair DM.
Molecular Psychiatry, 2011 Jan;16(1):17-25. Epub 2009 Sep 29. PubMed PMID: 19786961

122. White-matter markers for psychosis in a prospective ultra-high-risk cohort.
Bloemen OJN, de Koning MB, Schmitz N, Nieman DH, Becker HE, De Haan L, Dingemans P, Linszen DH, van Amelsvoort TAMJ.
Psychological Medicine 2010;40(8):1297-1304

121. Emotional Experience and Estimates of D2 Receptor Occupancy in Psychotic Patients Treated with Haloperidol, Risperidone, or Olanzapine: an Experience Sampling Study
Lataster J, van Os J, De Haan L, Thewissen V, Bak M, Lataster T, Lardinois M, Delespaul P, Myin-Germeys, I
The Journal of Clincial Psychiatry, 2010 Dec 14. [Epub ahead of print]

120. Kraepelin was right: a latent class analysis of symptom dimensions in patients and controls.
Derks EM, Allardyce J, Boks MP, Vermunt JK, Hijman R, Ophoff RA; GROUP.
Schizophrenia Bulletin 2010 Sep 30. [Epub ahead of print]

119. Insight in psychosis: relationship with neurocognition, social cognition and clinical symptoms depends on phase of illness
Quee PJ, Van der Meer L, Bruggeman R, De Haan L, Krabbendam L, Cahn W, Mulder N, Wiersma D, Aleman A
Schizophrenia Bulletin 2011 Jan;37(1):29-37. Epub 2010 Nov 22

118. Off-label second generation antipsychotics for impulse regulation disorders: a review.
Beduin AS, De Haan L.
Psychopharmacol Bull. 2010;43(3):45-81

117. Reply to Fan and Hart.
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, De Haan L.
Psychiatry Research. 2011 Jan 30;191(1):85. Epub 2010 Nov 10

116. Obsessive – compulsive symptoms in first episode psychosis and in subjects at ultra high risk for developing psychosis; onset and relationship to psychotic symptoms.
Sterk B, Lankreijer K, Linszen D, De Haan L.
The Royal Australian and New Zealand College of Psychiatrists. 2010 Nov 18. [Epub ahead of print]

115. Family-based Analysis of Genetic Variation Underlying Psychosis-Inducing Effects of Cannabis: Sibling Analysis and Proband Follow-Up.
Van Winkel R, GROUP Investigators.
Archives of General Psychiatry. Published online 2010 November 1

114. Social functioning among older community-dwelling patients with schizophrenia: a review
Meesters PD, Stek M, Comijs HC, De Haan L , Patterson TL, Eikelenboom P, Beekman ATF
The American Journal of geriatric psychiatry 2010 Oct;18(10):862-78

113. Neurocognitive functioning before and after a First psychotic episode: Does psychosis result in cognitive deterioration?
Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, De Haan L, van Amelsvoort A, Linszen DH.
Psychological Medicine, Psychol Med. 2010 Oct;40(10):1599-606. Epub 2010 Feb 5

112. Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder.
Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, Georgieva L, Williams NM, Morris DW, Quinn EM, Giegling I, Ikeda M, Wood J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, Maher BS; Molecular Genetics of Schizophrenia Collaboration (MGS) International Schizophrenia Consortium (ISC), SGENE-plus, GROUP, Malhotra AK, Riley B, Kendler KS, Gill M, Sullivan P, Sklar P, Purcell S, Nimgaonkar VL, Kirov G, Holmans P, Corvin A, Rujescu D, Craddock N, Owen MJ, O'Donovan MC.
Mol Psychiatry. 2010 Apr 6. [Epub ahead of print]

111. Disability in people clinically at high risk for a psychosis
Velthorst E, Nieman D, Linszen D, Becker H, De Haan L, Dingemans P, Birchwood M, Patterson P, Salokangas R, Heinimaa M, Heinz A, Juckel G, Graf von Reventlow H, French P, Stevens H, Schultze-Lutter F, Klosterkötter J, Ruhrmann S
British Journal of Psychiatry. 2010 Oct; 197, (4), 278-84

110. Environmental factors and social adjustment as predictors of a first psychosis in subjects at ultra high risk
Dragt S, Nieman DH, Veltman D, Becker HE, Van de Fliert R, De Haan L, Linszen DH
Schizophrenia Research. 2010 Sept 29 [Epub ahead of print] PMID: 20884179

109. Symptomatic remission and associated factors in a catchment area based population of older patients with schizophrenia.
Meesters PD, Comijs HC, De Haan L, MD, Smit JH, Eikelenboom P, Beekman ATF, Stek M
Schizophrenia Research. 2010 Sep 29 [PubMed - as supplied by publisher] PMID: 20888190

108. Effect of Early Dysphoric Response and Cannabis Use on Discontinuation of Olanzapine or Risperidone in Patients With Early Psychosis.
Nimwegen-Campailla LV, Beveren NV, Laan W, Brink WV, Linszen D, De Haan L
Pharmacopsychiatry. 2010 Sep 13. PubMed PMID: 20839158

106. Social functioning among older community-dwelling patients with schizophrenia: a review
Meesters PD, Stek M, Comijs HC, De Haan L , Patterson TL, Eikelenboom P, Beekman ATF
The American Journal of geriatric psychiatry, 2010s

105. Expanding the range of ZNF804A variants conferring risk of psychosis.
Steinberg S, Mors O, Børglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Böttcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietiläinen OP, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Athanasiu L, Suvisaari J, Lonnqvist J, Paunio T, Hartmann A, Jürgens G, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Breuer R, Möller HJ, Giegling I, Glenthøj B, Rasmussen HB, Mattheisen M, Bitter I, Réthelyi JM, Sigmundsson T, Fossdal R, Thorsteinsdottir U, Ruggeri M, Tosato S, Strengman E; GROUP, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Walshe M, Bramon E, Vassos E, Li T, Fraser G, Walker N, Toulopoulou T, Yoon J, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Jönsson EG, Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Peltonen L, Rujescu D, Collier DA, Stefansson H, St Clair D, Stefansson K
Molecular Psychiatry advance online publication 5 January 2010; doi: 10.1038/mp.2009.149

104. Copy number variations of chromosome 16p13.1 region associated with schizophrenia
Ingason A, Rujescu D, Cichon S, Sigurdsson E, Sigmundsson T, Pietiläinen OP, Buizer-Voskamp JE, Strengman E, Francks C, Muglia P, Gylfason A, Gustafsson O, Olason PI, Steinberg S, Hansen T, Jakobsen KD, Rasmussen HB, Giegling I, Möller HJ, Hartmann A, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Bramon E, Kiemeney LA, Franke B, Murray R, Vassos E, Toulopoulou T, Mühleisen TW, Tosato S, Ruggeri M, Djurovic S, Andreassen OA, Zhang Z, Werge T, Ophoff RA; GROUP Investigators, Rietschel M, Nöthen MM, Petursson H, Stefansson H, Peltonen L, Collier D, Stefansson K, Clair DM.
Molecular Psychiatry advance online publication 29 September 2009; doi: 10.1038/mp.2009.101

103. Duration of untreated psychosis and ethnicity
Sterk B, Slief EM, Blankers M, Linszen DH, De Haan L
Schizophr Res. 2010 Aug 17. [Epub ahead of print]

102. Three year course of clinical symptomatology in young people at ultra high risk for transition to psychosis
Velthorst E, Nieman DH, Klaassen RMC, Becker HE, Dingemans PM, Linszen DH, De Haan L
Acta Psychiatrica Scandinavica, 2010

101. An exploratory analysis of factors associated with weight change in a 16 week trial of oral versus orally disintegrating olanzapine: the PLATYPUS study
Karagianis J, Landry J, Hoffmann VP, Grossman L, De Haan L, Maguire G, Milev R, Holt S
International Journal of Clinical Practice, 2010, 64, 11, 1520-1529

100. Cannabis use in patients with a first psychotic episode and subjects at Ultra High Risk of psychosis: impact on psychotic- and pre-psychotic symptoms.
Machielsen M, Van der Sluis S, De Haan L
Australian and New Zealand Journal of Psychiatry, 2010, 44 [8], 721-728

99. Reduced parietal P300 amplitude is associated with an increased risk for a first psychotic episode
Van Tricht MJ, Nieman DH, Koelman JHTM, Van der Meer J, Bour LJ, De Haan L, Linszen D
Biological Psychiatry, 2010 Epub

98. Diffusion Tensor Imaging in the Early Phase of Schizophrenia: What Have We Learned?
Peters BD, Blaas J, De Haan L
Journal of Psychiatric Research, 2010

97. Dopaminergic modulation of human reward system: a placebo controlled dopamine depletion fMRI study
Da Silva Alves F, Schmitz N, Figee M, Abeling N, Hasler G, Van der Meer J, Nederveen A, De Haan L, Linszen DH, Van Amelsvoort T
Journal of Psychopharmacology, 2010 Jun 8

96. Increased saccadic rate during Smooth Pursuit Eye Movements in patients at Ultra High Risk for developing a psychosis
Van Tricht MJ, Nieman DH, Bour LJ, Boeree T; Koelman JH, De Haan L, Linszen DH
Brain and Cognition 2010 Jun 8. [Epub ahead
of print] PubMed PMID: 20538400

95. Reduced context effects on retrieval in first-episode schizophrenia
Talamini LM, De Haan L, Nieman DH, Linszen DH, Meeter M
Plos One, 2010 Apr 27;5(4):e10356

94. Age at onset of cannabis use is associated with age at onset of high-risk symptoms for psychosis.
Dragt, S. Nieman DH, Becker HE; Van de Fliert R, Dingemans PM, De Haan L, van Amelsvoort TA, Linszen DH. Canadian Journal of Psychiatry, 2010, 55(3): 165-171

93. A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. Ingason A, Giegling I, Cichon S, Hansen T, Rasmussen HB, Nielsen J, Jürgens G, Muglia P, Hartmann AM, Strengman E, Vasilescu C, Mühleisen TW, Djurovic S, Melle I, Lerer B, Möller HJ, Francks C, Pietiläinen OP, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Walshe M, Vassos E, Di Forti M, Murray R, Bonetto C, Tosato S; Genetic Risk and Outcome in Psychosis (GROUP), Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman
R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I., Cantor RM, Rietschel M, Craddock N, Owen MJ, Peltonen L, Andreassen OA, Nöthen MM, St Clair D, Ophoff RA, O'Donovan MC, Collier D, Werge T, Rujescu D. Hum Mol Genet. 2010 Apr 1;19(7):1379-86. Epub 2010 Jan 12. PubMed PMID: 20071346;
PubMed Central PMCID: PMC2838541.

92. Symptomatology and neuropsychological functioning in cannabis using subjects at ultra high risk for developing psychosis and healthy controls. Korver N, Nieman DH, Becker HE, Van de Fliert JR, Dingemans PM, De Haan L, Spiering M, Schmitz N, Linszen DH. Australian and New Zealand Journal of Psychiatry, 2010 44(3) 230-6

91. Verbal fluency as a possible predictor for psychosis.
Becker HE, Nieman DH, Dingemans PM, van de Fliert JR, De Haan L, Linszen DH.
Eur Psychiatry. [Epub ahead of print] PubMed PMID: 20005685

90. Differences in efficacy on substance abuse between Risperidone and Clozapine supports the importance of differential modulation of dopaminergic neurotransmission.
Psychopharmacol Bull. 2009;42(4):40-52.
Machielsen MW, de Haan L

89. Subjective effects of cannabis before the first psychotic episode.
Peters BD, de Koning P, Dingemans P, Becker H, Linszen DH, De Haan L
Aust N Z J Psychiatry. 2009 Dec;43(12):1155-62

88. Neurocognitive functioning before and after the first psychotic episode: Does psychosis result in cognitive deterioration?
HE Becker, DH Nieman, S Wiltink, PM Dingemans, JR VD Fliert, De Haan L, TA van Amelsvoort, DH Linszen
Psychological Med. 2009

87. Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission
Machielsen M, De Haan L
Psychopharmacol Bull. 2009; 42(4):40-52

86. Cannabis use and callosal white matter structure and integrity in recent-onset schizophrenia.
Dekker N, Schmitz N, Peters BD, van Amelsvoort TA, Linszen DH, De Haan L.
Psychiatry Res. 2009

85. White matter connectivity and psychosis in ultra-high-risk subjects: A diffusion tensor fiber tracking study.
Peters BD, Dingemans PM, Dekker N, Blaas J, Akkerman E, van Amelsvoort TA,
Majoie CB, den Heeten GJ, Linszen DH, De Haan L.
Psychiatry Res. 2009 Nov 30. PubMed PMID: 19954931

84. Implicit and explicit affective associations towards cannabis use in patients with recent-onset schizophrenia and healthy controls.
Dekker N, Smeerdijk AM, Wiers RW, Duits JH, van Gelder G, Houben K, Schippers
G, Linszen DH, De Haan L.
Psychol Med. 2010 Aug;40(8):1325-36. Epub 2009 Nov 17.

83. Remission of schizophrenia psychosis and strong reduction of obsessive-
compulsive disorder after adding clozapine to aripiprazole.
Peters B, De Haan L.
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Sep 17

82. Reasons for Cannabis Use and Effects of
Cannabis Use as Reported by Patients with Psychotic Disorders.
Dekker N, Linszen DH, De Haan L.
Psychopathology. 2009 Sep 15;42(6):350-360

81. Crisis intervention and acute psychiatry in Amsterdam: 20 years of change.
van der Post LF, Jonkers JF, Beekman AT, Mulder CL, De Haan L, Mulder WG,
Schoevers RA, Dekker JJ.
Int J Soc Psychiatry. 2010 Jul 17

80. Recent-onset schizophrenia and adolescent cannabis use: MRI evidence for
structural hyperconnectivity?
Peters BD, De Haan L, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH.
Psychopharmacol Bull. 2009;42(2):75-88

79. Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study.
Peters BD, Duran M, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH, de Haan L.
Prostaglandins Leukot Essent Fatty Acids. 2009 Jul;81(1):61-3. Epub 2009 May 23

78. Common variants conferring risk of schizophrenia.
Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge
T, Pietiläinen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M,
Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T,
Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D,
Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I,
Rasmussen HB, Timm S, Mattheisen M, Bitter I, Réthelyi JM, Magnusdottir BB,
Sigmundsson T, Olason P, Masson G, Gulcher JR, Haraldsson M, Fossdal R,
Thorgeirsson TE, Thorsteinsdottir U, Ruggeri M, Tosato S, Franke B, Strengman E,
Kiemeney LA, GROUP, Melle I, Djurovic S, Abramova L, Kaleda V, Sanjuan J, de
Frutos R, Bramon E, Vassos E, Fraser G, Ettinger U, Picchioni M, Walker N,
Toulopoulou T, Need AC, Ge D, Lim Yoon J, Shianna KV, Freimer NB, Cantor RM,
Murray R, Kong A, Golimbet V, Carracedo A, Arango C, Costas J, Jönsson EG,
Terenius L, Agartz I, Petursson H, Nöthen MM, Rietschel M, Matthews PM, Muglia P,
Peltonen L, St Clair D, Goldstein DB, Stefansson K, Collier DA; Genetic Risk and
Outcome in Psychosis (GROUP), Kahn RS, Linszen DH, van Os J, Wiersma D, Bruggeman
R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I.
Nature. 2009 460, 744-7

77. Prevalence of Psychotic Disorders in patients with an Obsessive-Compulsive Disorder
De Haan L, Dudek-Hodge C, Verhoeven Y, Denys, D
CNS spectrums, 2009, 14(8), 415-417

76. Polyunsaturated fatty acids and brain white matter anisotropy in recent-onset schizophrenia: a preliminary study.
Peters BD, Duran M, Vlieger EJ, Majoie CB, den Heeten GJ, Linszen DH, de Haan L.
Prostaglandins Leukot Essent Fatty Acids. 2009 Jul;81(1):61-3. Epub 2009 May 23

75. Fewer symptoms vs. more side-effects in schizophrenia? Opposing pathways between antipsychotic medication compliance and quality of life.
Staring AB, Mulder CL, Duivenvoorden HJ, De Haan L, Van der Gaag M.
Schizophrenia research, 2009, 113, 27-33

74. Subjective Effects of Cannabis Before the First Psychotic Episode deze staat al genoemd
Peters BD, De Koning P, Dingemans P, Becker H, Linszen DH, De Haan L

73. The prescription of antipsychotic medication to patients at ultra high risk for developing psychosis
Nieman DH, Rike WH, Becker HE, Dingemans PM, Van Amelsvoort TA, De Haan L, Van der Gaag M, Denys DA, Linszen DH
International Clinical Psychopharmacology, 2009, 24, 223-228

72. Preliminary Evidence for Reduced Frontal White Matter Integrity in Subjects at Ultra-High-
Risk for Psychosis
Peters B, Schmitz N, Dingemans P, Van Amelsvoort A, Majoie C, Den Heeten G, Linszen D, De Haan L
Schizophrenia research, 2009, 111, 192-193

71. A Randomized Controlled Trial of the Effect of Sublingual Orally Disintegrating Olanzapine Versus Oral Olanzapine on Body Mass Index: the PLATYPUS Study
Karagianis J, Grossman L, Landry J, Reed VA, De Haan L, Maguire J, Hoffmann VP, Milev R
Schizophrenia research, 2009, 113, 41-48

70. Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis
Velthorst E, Nieman D, Becker H, Van de Fliert R, Dingemans P, Klaassen R, De Haan L, Van Amelsvoort T, Linszen D
Schizophrenia Research 2009, 109, 60-65

69. Striatal D2 receptor binding in 22q11 Deletion Syndrome: an [123I]IBZM SPECT study
Boot E, Booij J, Zinkstok JR, De Haan L, Linszen DH, Baas F, Van Amelsvoort TA
Journal of Psychopharmocology 2009

68. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine
or risperidone
Van Bruggen M, Van Amelsvoort T, Wouters L, Dingemans P, De Haan L, Linszen D
Psychoneuroendocrinology (2009, IF: 4.4), 34, 989-995

67. Disruption of the neurexin 1 gene is associated with schizophrenia.
Rujescu D, Ingason A, Cichon S, Pietiläinen OP, Barnes MR, Toulopoulou T, Picchioni M, Vassos E, Ettinger U, Bramon E, Murray R, Ruggeri M, Tosato S, Bonetto C, Steinberg S, Sigurdsson E, Sigmundsson T, Petursson H, Gylfason A, Olason PI, Hardarsson G, Jonsdottir GA, Gustafsson O, Fossdal R, Giegling I, Möller HJ, Hartmann A, Hoffmann P, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Andreassen OA, Djurovic S, Hansen T, Werge T, Melle I, Kiemeney LA, Franke B, Buizer-Voskamp JE, Ophoff RA; GROUP Investigators: Kahn RS, Linszen DH, Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I Rietschel M, Nöthen MM, Stefansson K, Peltonen L, St Clair D, Stefansson H, Collier DA.
Hum Mol Genet. 2009; 18(5):988-96 (IF 7.8)

66. White Matter Fibertracking in First-Episode Schizophrenia, Schizoaffective Patients and Subjects at Ultra-High Risk of Psychosis.
Peters BD, De Haan L, Dekker N, Blaas J, Becker HE, Dingemans PM, Akkerman EM, Majoie CB, van Amelsvoort T, den Heeten GJ, Linszen DH.
Neuropsychobiology. 2008 ; 58(1):19-28. (IF 2.4)

65. Recurrent CNVs disrupt three candidate genes in schizophrenia patients.
Vrijenhoek T, Buizer-Voskamp JE, van der Stelt I, Strengman E; Genetic Risk and Outcome in Psychosis (GROUP) Consortium: Kahn RS, Linszen DH, Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I, Sabatti C, Geurts van Kessel A, Brunner HG, Ophoff RA, Veltman JA.
Am J Hum Genet. 2008 Oct;83(4):504-10. (IF 11.1)

64. Cocaine is a major Risk Factor for Antipsychotic Induced Akathisia, Parkinsonism and Dyskinesia.
Maat A, Fouwels A, De Haan L
Psychopharmacology Bulletin 2008;41(3):5-10 (IF: 1.7)

63. Recurrent microdeletions associated with schizophrenia
Stefansson H, Rujescu D, Cichon S, Pietiläinen OPH, Ingason A, Fossdal A, Steinberg S, Sigurdsson E, Sigmundsson T, Buizer-Voskamp JE, Hansen T, Jakobsen KD, Muglia P, Francks C, Matthews PM, Gylfason A, Halldorsson BV, Gudbjartsson D, Thorgeirsson TE, Sigurdsson A, Jonasdottir A, Jonasdottir A, Bjornsson A, Mattiasdottir S, Blondal T, Haraldsson M, Magnusdottir BB, Giegling I, Möller HJ, Hartmann A, Shianna KV, Ge D, Need AC, Crombie C, Fraser G, Walker N, Lonnqvist J, Suvisaari J, Tuulio-Henriksson A, Paunio T, Toulopoulou T, Bramon T, Di Forti M, Murray R, Ruggeri M, Vassos E, Tosato S, Walshe M, Li T, Vasilescu C, Mühleisen TW, Wang AG, Ullum H, Djurovic S, Melle I, Olesen J, Kiemeney LA, Franke B, GROUP Investigators: Kahn RS, Linszen DH, Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I, , Sabatti C, Freimer NB, Gulcher JR, Thorsteinsdottir U, Kong A, Andreassen OA, Ophoff R, Georgi A, Rietschel M, Werge T, Petursson H, Goldstein D, Nöthen MM, Peltonen L, Collier D, St Clair D, Stefansson
Nature, 2008; 455(7210):232-6 (IF: 26.7)

62. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.
Van Nimwegen LJ, De Haan L, van Beveren NJ, van der Helm M, van den Brink W, Linszen D.
Can J Psychiatry. 2008 Jun;53(6):400-5. (IF: 2.5)

61. Schizophrenia aetiology: D gene-environment interactions hold the key?
Van Os, Leboyer M, Meyer-Lindenberg A, Stefanis N, GROUP Investigators: Kahn RS, Linszen DH, Os J, Wiersma D, Bruggeman R, Cahn W, De Haan L, Krabbendam L, Myin-Germeys I Arango C, Jones P, Kapur S, Lewis S, Murray R, Owen MJ
Schizophrenia Research, 2008, 102: 21-26

60. The Amsterdam Studies of Acute Psychiatry I (ASAP-I); a prospective cohort study of determinants and outcome of coercive versus voluntary treatment interventions in a metropolitan area.
Van der Post L, Schoevers R, Koppelmans V, Visch I, Bernardt C, Mulder N,
Beekman A, De Haan L, Dekker J.
BMC Psychiatry. 2008 14;8:35 (IF: 2.9)

59. A visual metaphor describing neural dynamics in schizophrenia
Van Beveren N, De Haan L
PlosOne 2008, 3 (7): e2577. doi:10.1371/journal.pone.0002577

58. Obsessive-Compulsive Symptoms in a Randomized, Double-Blind Study With Olanzapine or Risperidone in Young Patients With Early Psychosis.
Van Nimwegen L, De Haan L, van Beveren N, Laan W, van den Brink W, Linszen D.
J Clin Psychopharmacol. 2008 28(2):214-218. (IF: 4.6)

57. Cessation of cannabis use by patients with recent-onset schizophrenia and related disorders
Dekker N, De Haan L, Van den Berg S, De Gier M, Becker H, Linszen D
Psychopharmacology Bulletin 2008; 41:142-53.(IF: 1.7)

56. The revised dopamine hypothesis of schizophrenia: Evidence from pharmacological MRI studies with atypical antipsychotic medication
DaSilva F, Figee M, Van Amelsvoort T, Veltman D, De Haan L.
Psychopharmacology Bulletin 2008;41:121-32. (IF: 1.7)

55. Improvement of subjective well-being and enduring symptomatic remission, a 5 year follow up of first episode schizophrenia
De Haan L, van Nimwegen, T. van Amelsvoort, P. Dingemans, D. Linszen
Pharmacopsychiatry, 2008, 41(4):125-8.1-4. (IF: 3.2)

54. AMPT-induced monoamine depletion in humans: evaluation of two alternative [123] IBZM procedures
Boot E, Booij J, Hasler G, Zinkstok J, De Haan L, Linszen D, van Amelsvoort T.
European Journal of Nuclear Medicine and Molecular Imaging 2008; 35(7):1350-6. (IF: 4.0)

53. The Catechol-O-Methyltransferase Gene and Obsessive-Compulsive Symptoms in Patients with Recent-Onset Schizophrenia
Zinkstok J, van Nimwegen L, van Amelsvoort T, De Haan L, Abdulkadir M, Baas F, Linszen D.
Psychiatry Research, 2008, 15, 157:1-8

52. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
Karagianis J, Poole Hoffmann V, Arranz B, Treuer T, Maguire GA, De Haan L, Chawla B
Human Psychopharmacology: Clinical and Experimental 2008, 28 (2) 214-218 (IF: 2.4)

51. Hepatic insulin resistance in antipsychotic naive patients with schizophrenia, a detailed study of glucose metabolism with stable isotopes.
Van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, De Haan L,
Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJ, Sauerwein HP.
J Clin Endocrinol Metab. 2008, 93: 572-577 (IF: 5.8)

50. Risk factors for medication non-adherence in patients with first episode schizophrenia and related disorders; a prospective five year follow-up
De Haan L, van Amelsvoort T, Dingemans P, Linszen D
Pharmacopsychiatry. 2007 Nov;40(6):264-8. (IF: 3.2)

49. Catechol-O-methyltransferase gene and obsessive-compulsive symptoms in patients with recent-onset schizophrenia: Preliminary results.
Zinkstok J, Van Nimwegen L, Van Amelsvoort T, De Haan L, Yusuf MA, Baas F, Linszen D.
Psychiatry Res. 2008, 157:1-8 (IF: 2.3)

48. Disrupted Dopaminergic Neurotransmission in 22q11 Deletion Syndrome.
Boot E, Booij J, Zinkstok J, Abeling N, De Haan L, Baas F, Linszen D, van Amelsvoort T.
Neuropsychopharmacology.2008, 1252-1258 (IF: 5.9)

47. Effects of a functional COMT polymorphism on brain anatomy and cognitive function in adults with velo-cardio-facial syndrome.
Van Amelsvoort T, Zinkstok J, Figee M, Daly E, Morris R, Owen MJ, Murphy KC, De
Haan L, Linszen DH, Glaser B, Murphy DG.
Psychol Med, 2008,38,89-100 (IF: 3.8)

46. Motivational Interviewing in psychotic disorders
Barkhof E, De Haan L, Meijer KJ, Fouwels AJ, Keet IPM, Hulstijn KP, Schippers GM, Linszen DH
Current Psychiatry Reviews, 2006 (IF: 1.10)

45. Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients
De Haan L, Hoogenboom B, Beuk N, Wouters L, Dingemans P, Linszen D
Psychopharmacology Bulletin, 2006, 39, 25-30 (IF: 1.43)

44. Schizophrenia-associated neural growth factors in peripheral blood. A review
Van Beveren, NJM Van der Spelt, De Haan L, Fekkes,
European Neuropsychopharmacology, 2006, 16, 469-480 (IF: 3.51)

43. The five-factor model of the Positive and Negative Syndrome Scale I: Confirmatory factor analysis fails to confirm 25 published 5-factor solutions
Van der Gaag M, Cuijpers A, Hoffman T, Remijsen M, Hijman R, De Haan L, Van Meijel B, Van Harten P, Valmaggia L, De Hert M, Wiersma D
Schizophrenia Research, 2006, 85, 273-279 ( IF: 4.31)

42. The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model Schizophrenia Research
Van der Gaag M, Hoffman T, Remijsen M, Hijman R, De Haan L, Van Meijel B, Van Harten P, Valmaggia L, De Hert M, Cuijpers A, Wiersma D
Schizophrenia Research, 2006, 85, 280-287 (IF: 4.31)

41. Early Withdrawal in a Double-Blind Randomized Clinical Trial with Olanzapine and Risperidone Performed in Adolescents with First Psychosis
Van Nimwegen L, De Haan L
Psychophathology, 2006, 39, 158 (IF: 0.81)

40. Feelings of comfort, self-confidence and safety are related to dopamine D2 receptor occupancy by conventional and new generation antipsychotics
De Haan L, Lavalaye J, Booij J, Linszen D
American Journal of Psychiatry, 2005, 162, 1544-1545 (IF: 7.61)

39. Subjective experiences during dopamine depletion
De Haan L, Booij J, Lavalaye J, Van Amelsvoort T, Linszen D
American Journal of Psychiatry, 2005, 162, 1755 (IF: 7.61)

38. Olanzapine Treatment of Residual Positive and Negative Symptoms
De Haan L, Van Beveren N
American Journal of Psychiatry, 2005, 162: 1392-1393 (IF: 7.61)

37. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia
De Haan L, Booij J, Lavalaye J, Van Amelsvoort T, Linszen D
Psychopharmacology, 2006, 183, 500-505 (IF: 3.99)

36. Modelling the treated course of schizophrenia: Development of a Discrete Event Simulation Model
Heeg BMS, Buskens E, Knapp M, VanCuijpers A, Aalst G, Dries PJT, De Haan L, Van Hout BA
PharmacoEconomics, 2005, 23, 17-33 (IF: 2.20)

35. Obsessive-compulsive symptoms and positive, negative, and depressive symptoms in patients with recent-onset schizophrenic disorders
De Haan L, Hoogenboom B, Beuk N, Van Amelsvoort T, Linszen D
The Canadian Journal of Psychiatry, 2005, 50 ,519-524 (IF: 2.18)

34. Adolescence, schizophrenia and drug abuse: a window of vulnerability.
Van Nimwegen L, De Haan L, Van Beveren N, Van den Brink W, Linszen D
Acta Psychiatryca Scandinavia, 2005, 427: 35-42 (IF: 2.97)

33. Weight loss after switching from conventional olanzapine to orally disintegrating olanzapine tablets
De Haan L, Van Amelsvoort T, Rosien K, Linszen D
Psychopharmacology, 2004, 175: 389-390 (IF: 3.99)

32. Obsessive-Compulsive Disorder and treatment with clozapine in 200 patients with recent-onset schizophrenia or related disorders
De Haan L, Oekeneva A, Van Amelsvoort T, Linszen D
European Psychiatry, 2004, 19, 524 (IF: 1.27)

31. Elevated homocysteine levels in schizophrenia
De Haan L, Van Amelsvoort T, Linszen D
American Journal of Psychiatry, 2004, 161, 1131-1132 (IF: 7.61)

30. Risperidone-induced leucopenia and neutropenia: a case report
Sluys M, Güzelcan Y, Casteelen G, De Haan L
European Psychiatry, 2004, 19, 117 (IF: 1.27)

29. Olanzapine vs haloperidol for treatment of schizophrenia
De Haan L, Van Beveren N
JAMA, 2004, 291, 1065 (IF: 23.33)

28. Pericardial and bilateral pleural effusion associated with clozapine treatment
Boot E, De Haan L, Guzelcan Y, Scholte P, Assies H
European Psychiatry, 2004, 19, 65-66 (IF: 1.27)

27. Opinions of mothers towards the first psychotic episode and the start of treatment of their child
De Haan L, Welborn K, Krikke M, Linszen D
European Psychiatry, 2004, 19: 226-229 (IF: 1.27)

26. Early intervention in first epsiode psychosis and schizophrenia: a critical period for patients, families, and professionals
Linszen D, De Haan L, Van Amelsvoort T
Advances in Schizophrenia and Clinical Psychiatry, 2004, 1:11-15 (IF: 1.27)

25. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics; Clinical implications of neuroimaging
De Haan L, Lavalaye J, Van Bruggen M, Van Nimwegen L, Booij J, T van Amelsvoort, Linszen DH
The Canadian Journal of Psychiatry, 2004, 49: 290-296 (IF: 2.18)

24. Overview of neuropathological theories of schizophrenia: from degeneration to progressive developmental disorder
De Haan L, Bakker JM
Psychopathology, 2004, 37: 1-7 (IF: 0.81)

23. School performance in secondary education shows no decline before the onset of a first episode of psychosis in schizophrenia.
van der Gaag M, Wolthaus J, De Haan L, Wykes T
Journal of Mental Health, 2003, 12: 585- 594 (IF: 1.82)

22. Duration of untreated psychosis and outcome of schizophrenia: delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication
De Haan L, Linszen DH, Lenior ME, Doderlein de Win E, Gorsira R
Schizophrenia Bulletin, 2003, 29: 341-348 (IF: 2.87)

21. Suicide risk in placebo versus the active treatment in placebo-controlled trials for schizophrenia
Storosum JG, Van Zwieten BJ, Wohlfarth T, De Haan L, Khan A, Van den Brink W
Archives of Psychiatry, 2003, 60: 365-368 (IF: 11.21)

20. Subjective experience and D2 receptor occupancy in patients with schizophrenia, treated with low dose Olanzapine or Haloperidol; a randomized double-blind study
De Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans P, Linszen D
American Journal of Psychiatry, 2003, 160: 303-309 (IF: 7.61)

19. Attitudes of Patients towards the First Psychotic Episode and the Start of Treatment
De Haan L, Peters B, Dingemans P, Wouters L, Linszen D
Schizophrenia Bulletin, 2002, 28(3): 431-442 (IF: 2.87)

18. Priorities and satisfaction on the help needed and provided in a first episode of psychosis
A survey in five European Family Associations
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L
European Psychiatry, 2002, 17: 425-433 (IF: 1.27)

17. Obsessive-Compulsive Symptoms during treatment with olanzapine and risperidone, a prospective study of 113 patients with recent-onset schizophrenia or related disorders
De Haan L, Beuk N, Hoogenboom B, Dingemans PMAJ, Linszen DH
The Journal of Clinical Psychiatry, 2002, 63: 104-107 (IF: 5.04)

16. Comparable Dopamine 2 receptor occupancy
De Haan L, Van Amelsvoort T
American Journal of Psychiatry, 2002, 159, 2118 (IF: 7.61)

15. Informed consent from behaviourally disturbed patients
Storosum JG, van Zwieten BJ, De Haan L
The Lancet, 2002, 359, 83 (IF: 23,41)

14. Psychometric properties of the Subjective Well-being under Neuroleptics scale (SWN) and the Subjective Deficit Syndrome Scale (SDSS)
De Haan L, Weisfelt M, Dingemans PMAJ, Linszen DH, Wouters L
Psychopharmacology, 2002, 162:24-28 (IF: 3.99)

13. Olanzapine-induced obsessive-compulsive symptoms in a patient with bipolar II disorder
Jonkers F, De Haan L
Psychopharmacology, 2002, 162: 87-88 (IF: 3.99)

12. Risperidone may induce mania
Güzelcan Y, De Haan L, Scholte WF
Psychopharmacology, 2002, 162: 85-86 (IF: 3.99)

11. Preferences for treatment during a first psychotic episode
De Haan L, van Raaij B, van den Berg R, Jager M, Houweling P,
Stockmann M, Delsing P, Linszen D, Peters B, Wouters L
European Psychiatry, 2001, 16: 83-89 (IF: 1.27)

10. Social functioning and the course of early-onset schizophrenia. Five-year follow-up of a psychosocial intervention
Lenior ME, Dingemans PMAJ, Linszen DH, De Haan L, Schene AH
British Journal of Psychiatry, 2001, 179: 53-58 (IF: 4.61)

9. Dr. De Haan and colleagues reply to Bressan et al.: Dopamine D2 receptor blockade in schizophrenia
De Haan L, Lavalaye J, Linszen DH, Dingemans PMAJ, Booij J
American Journal of Psychiatry, 2001, 158: 972 (IF: 7.61)
8. Interaction of olanzapine with fluvoxamine
De Jong J, Hoogenboom B, Doude van Troostwijk L, De Haan L
Psychopharmacology, 2001, 151: 219-220 (IF: 3.99)

7. Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized on olanzapine or risperidone
De Haan L, Lavalaye J, Linszen DH, Dingemans PMAJ, Booij J
American Journal of Psychiatry, 2000, 157:1019-1020 (IF: 7.61)

6. Duration of untreated psychosis and the long-term course of schizophre¬ni¬a
De Haan L, van der Gaag M, Wolthaus J
European Psychiatry, 2000, 15: 264-267(IF: 1.27)

5. Massive increase in serum creatine kinase (CPK) during olanzapine and quetiapine treatment, not during treatment with clozapine
Boot E, De Haan L
Psychopharmacology, 2000, 150: 347-348 (IF: 3.99)

4. Clozap¬ine and obsessions in pa¬tients with recent onset schi¬zophrenia and other psychotic disorders
De Haan L, Linszen DH, Gorsira R
The Journal of Clinical Psychiatry, 1999, 60:364-365 (IF: 5.04)

3. Early intervention, social functioning and psychotic relapse of patients with recent-onset schizophrenic disorders
De Haan L, Linszen DH, Gorsira R
International Clinical Psychopharmacology, 1998, 63-66 (IF: 2.75)

2. Early intervention, untreated psychosis and the course of early schizophrenia
Linszen DH, Lenior ME, De Haan L, Dingemans PMAJ, Gersons BPR
British Journal of Psychiatry, 1998, 84-89 (IF: 4.61)

1. Early detection and intervention in schizophrenia
Linszen DH, Dingemans PMAJ, Lenior ME, Scholte WF, De Haan L, Goldstein MJ
International Clinical Psychopharmacology, 1998, 31-34 (IF: 2.75)

National (refereed) journals

52. Vrouwen, schizofrenie en oestrogeen; neurobiologische hypothesen en interventiestudies
Boerma MAM, Van der Stel JC, Van Amelsvoort T, Linszen DH, De Haan L
Tijdschrift voor Psychiatrie 52 (2010) 4, 235-244

51. Mulder CL, van der Gaag M, Bruggeman R, Cahn W, Delespaul PA, Dries P, Faber
G, De Haan L, van der Heijden FM, Kempen RW, Mogendorff ES, Slooff CJ, Sytema S,
Wiersma D, Wunderink L, van Os J.
Routine Outcome Monitoring for patients with severe mental illness: a consensus document.
Tijdschr Psychiatr. 2010;52(3):169-79

50. Bewegen. [Editorial]
de Haan L
Tijdschr Psychiatr. 2009;51(5):275-7

49. Veranderingen in crisisinterventie en acute psychiatrie; Amsterdamse consulten in 1983 en 2005
Van der Post L, Dekker J, Jonkers J, Beekman A, Mulder C, De haan L, Mulder W, Schoevers R
Tijdschrift voor psychiatrie, 51 (2009) 3, 139 - 150

48. 25 years antipsychotics: back to the future?
Denys D, de Haan L
Tijdschr Psychiatr. 2008;50(13):105-9

47. Preventie en behandeling van somatische complicaties bij antipsychoticagebruik
Cahn W, Ramlal D, Bruggeman R, De Haan L, Scheepers FE, van Soest MM, Assies J, Slooff CJ
Tijdschrift voor Psychiatrie 50 (2008) 9, 579-591

46. Voorkom! [Editorial]
De Haan L.
Tijdschr Psychiatr. 2008; supplement Voorjaarscongres Nederlandse Vereniging voor Psychiatrie

45. Alledaagse vragen en wetenschap [Editorial]
De Haan L.
Tijdschr Psychiatr. 2007;49(11):785-8.

44. [Adolescence, schizophrenia and drug abuse: interactive vulnerability. A hypothesis]
van Nimwegen L, De Haan L, van Beveren N, van den Brink W, Linszen D.
Tijdschrift voor Psychiatrie. 2007;49:169-78

43. Probleeminventarisatie vanuit clienten met een psychose: toepasbaarheid van de Canadian Occupational Performance Measure (COPM)
Teunissen S, Bolten M, De Wilde O, De Haan L
Rehabilitatie, 2007, 1: 35-40

42. Ontwikkeling van psychopathologie [Editorial] [Development of psychopathology]
De Haan L
Tijdschrift voor Psychiatrie. 2006, 48:359-60

41. Boekbespreking: Murphy KC, Scambler PJ: Velo-cardio-facial syndrome: a model for understanding microdeletion disorders
De Haan L
Tijdschrift voor Psychiatrie, 2006, 48, 574

40. Klinische respons op antipsychotica al binnen 24 uur
Dekker N, De Haan L
Tijdschrift voor Psychiatrie, 2006, 48, 242

39. Effectiviteit van antipsychotica bij patiënten met chronische schizofrenie
Schulte PFJ, De Haan L
Tijdschrift voor Psychiatrie, 2006, 48, 243-244

38. Resterende neuropsychologische stoornissen, structurele en functionele hersenafwijkingen na langdurig cannabisgebruik
Weeda MR, Peters BD, De Haan L , Linszen DH
Tijdschrift voor Psychiatrie, 2006, 48, 185-193

37. Het optimale niveau van dopaminerge neurotransmissie
De Haan L
Nederlands Tijdschrift voor Geneeskunde, 2005, 149, 1721-1722

36. Psychose en intellectuele prestatie
Van Nimwegen L, De Haan L
Tijdschrift voor Psychiatrie, 2005, 47, 558

35. De “delayed-onset hypothese” van het effect van antipsychotica: getoetst en verworpen.
Dekker N, De Haan L
Tijdschrift voor Psychiatrie, 2004, 46, 781

34. Loont het om nieuwe-generatie antipsychotica te gebruiken ter voorkoming van terugval bij schizofrenie?
De Haan L
Maandblad Geestelijke Volksgezondheid, 2004, 59, 852-855

33. Boekbespreking: Eling P, de Haan E, Hijman R, Schmand B: Cognitieve neuropsychiatrie
De Haan L
Tijdschrift voor Psychiatrie, 2004, 46, 442-443

32. Mannen met schizofrenie waarderen geur op een afwijkende wijze
De Haan L
Nederlands Tijdschrift voor Geneeskunde, 2004, 148, 544

31. Relevantie van het metabolisme van homocysteine voor de behandeling van schizofrenie
De Haan L, Güzelcan Y
Tijdschrift voor Psychiatrie, 2004, 46, 93-99

30. Genetisch onderzoek bij schizofrenie: een overzicht.
Figee M, Van Amelsvoort T, De Haan L, Linszen DH
Tijdschrift voor Psychiatrie, 2004, 46, 15-26

29. Boekbespreking: Schothorst PF, Emck C, Hop J: Jongeren met psychotische stoornissen, behandeling in een zorglijn.
De Haan L
Maandblad Geestelijke Volksgezondheid, 2003, 58: 972-974

28. Recensie: Solms, M. & Turnbull, O. The brain and the inner world. An introduction to the neuroscience of subjective experience.
De Haan L
Tijdschrift voor Psychiatrie, 2003, 45: 382

27. Dysconnectiviteit bij schizofrenie: afwijkingen in de witte stof van de hersenen
Peters BD, De Haan L, Linszen DH
Tijdschrift voor Psychiatrie, 2003, 45: 507-515

26. Dopamine, importantie en psychose
De Haan L, Kapur S
Maandblad Geestelijke Volksgezondheid, 2003, 58: 228-235

25. Boekbespreking: Aalsvoort, van der L.Met gezond verstand. Herstel van schizofrenie langs de natuurlijke weg.
De Haan L
Maandblad Geestelijke Volksgezondheid, 2003, 58: 306-308

24. Antwoord aan Verhoeven en Tuinier: schizofrenie en het 22q11 deletie syndroom
Vorstman JAS, Van Amelsvoort T, Güzelcan Y, De Haan L, De Ranitz AGS, Udink ten Cate FEA, Van Schaik P, Kahn RS, Linszen DH, Beemer FA
Nederlands Tijdschrift voor Geneeskunde, 2003, 44, 318

23. Cognitie, subjectieve ervaring, dopamine en antipsychotica
De Haan L
Tijdschrift voor Psychiatrie, 2002, 44, 759-766

22. Het 22q11 deletie syndroom en schizofrenie
Güzelcan Y, Van Amelsvoort T, De Haan L, Linszen DH, van Schaik P
Nederlands Tijdschrift voor Geneeskunde, 2002, 43, 2019-2021

21. Klinische consequenties van interactie tussen olanzapine en fluvoxamine
de Jong J, Hoogenboom B, Doude van Troostwijk L, De Haan L
Tijdschrift voor psychiatrie, 2002, 44, 703-707

20. De "schizofrenie" ontmanteld reactie op het artikel van P. Vlaminck
De Haan L
Maandblad Geestelijke volksgezondheid, 2002, 57: 659-660

19. Dopamine receptorbezetting door antipsychotica: een overzicht van SPECT en PET onderzoek
Lavalaye J, De Haan L, Linszen DH
Tijdschrift voor Psychiatrie, 2002, 44: 39-44

18. Neurobiologische hypothesen over de pathogenese van schizofrenie. Van degeneratie tot progressieve ontwikkelingsstoornis
Bakker JM, De Haan L
Tijdschrift voor Psychiatrie, 2001, 43: 21-29

17. Sociaal functioneren en het beloop van recent onstane schizofrenie. Een vervolgstudie over de eerste vijf jaar
Lenior ME, Dingemans PMAJ, Linszen DH, De Haan L, Schene AH
Tijdschrift voor Psychiatrie, 2001, 43: 219-232

16. Rehabilitatie van klassieke antipsychotica, een overzicht van meta-analyses
De Haan L, Van Bruggen M, Lavalaye J, Scholte WF, Wouters L, Storosum J, Linszen DH
Tijdschrift voor psychiatrie, 2001, 43: 259-264

15. Het beloop van schizofrenie gedurende vijf jaar na een eerste opname in de westerse wereld, een meta-analyse
De Haan L, Timmer T, Linszen DH, Wouters L, Lenior ME
Tijdschrift voor Psychiatrie, 2001, 43: 559-565

14. Vrouwen met schizofrenie: onderzoeksbevindingen en implicaties voor de behandeling
Peters E, De Haan L
Tijdschrift voor psychiatrie, 2001, 43: 639-644

13. Recensie: Scheepers F: The effects of atypical antipsychotics in the brain of schizophrenic patients
De Haan L
Maandblad Geestelijke volksgezondheid, 2001, 12, 1204-1205

12. Recensie: Harrison, P.J., & Roberts, G.W. (red.) The neuropathology of Schizophrenia
De Haan L
Tijdschrift voor Psychiatrie, 2001, 43, 834-835

11. Dwangsymptomen bij schizofrenie: aanwijzingen voor een aparte groep
Beuk N, De Haan L
Tijdschrift voor Psychiatrie, 2000, 42: 347-351

10. Effectiviteit van individuele psychotherapie bij schizofrenie. Een overzicht van recent onderzoek
De Haan L, Bakker JM
Tijdschrift voor Psychiatrie, 2000, 42: 751-758

9. Duur onbehandelde psychose en beloop van schizofrenie
De Haan L, Bottelier M
Tijdschrift voor Psychiatrie, 1999, 239-243

8. Psychosebehandeling met een lage dosering D2-antagonist
De Haan L, Maksmovic I
Tijdschrift voor Psychiatrie, 1999, 287-291

7. Verbetering van therapietrouw bij de behandeling van schizofrenie patienten met antipsychotica
De Haan L, Bremmer M
Tijdschrift voor Psychiatrie, 1999, 665-669

6. Reactie op "Comorbiditeit van psychiatrische stoornissen in de Nederlandse bevolking…" betreffende de gevoeligheid van de CIDI voor psychotische stoornissen
Dingemans PMAJ, De Haan L, Linszen DH
Tijdschrift voor Psychiatrie, 1999, 41:58-61

5. Regionale aanpak van initiele niet-affectieve psychosen (Reactie op Vlaminck)
Linszen DH, De Haan L, Scholte WF
Maandblad Geestelijke Volksgezondheid, 1999; 10:1061-1066

4. Subjectieve ervaringen van patiënten met schizo¬fre¬nie gerelateerd aan behan¬deling met antipsychotica
Ten Brink C, De Haan L, Kne¬gtering H
Tijdschrift voor Psychiatrie, 1998, 40: 238-245

3. Vroegtijdige intensieve interventie, sociaal functioneren, psychoserecidief en suicide bij patienten met recent onstane schizofrenie en verwante stoornissen
De Haan L, Linszen DH, Gorsira R
Tijdschrift voor Psychiatrie, 1997, 24-36

2. Gestructureerd klinisch interview voor de positieve en negatieve syndroom schaal (SCI-PANSS)
Linszen D, De Haan L, Kuipers T, Dingemans P
Academisch Medisch Centrum, Divisie Psychiatrie, 1994, Amsterdam

1. Systeemconsultatie op een opname afdeling
Maillette de Buy Wenniger WF, De Haan L
Tijdschrift voor psychotherapie, 1992; 18: 2-11

Books or contributions to books

Brochure: Voor het eerst een psychose
De Haan L, Stavenuiter B, Stockmann M, Vlaminck P
38 pagina's
Ypsilon, 2009

Preventie en behandeling van somatische complicaties bij antipsychoticagebruik 2009
Cahn W, Ramlal D, Bruggeman R, De Haan L, Scheepers FE, Van Soest MM, Assies J, Slooff C
In: Complicaties bij behandeling van mensen met een psychose
Slooff C, Withaar F, Van der Gaag M
Koninklijke van Gorcum
Pag 503-523

Psychosen bij jeugdigen
De Haan L, Becker H
In: Leerboek voor kinder- en jeugd psychologie en psychiatrie
Dorelijer T, Huisman J, Vermeiren R, Boer F, De Haan E, Red
Pag 385-394

Medicamenteuze behandeling van psychotische stoornissen
De Haan L, Bruggeman R
In: Zorg rondom schizofrenie, Van Meijel B, Kuipers T, red
Pag 39-57
Bohn Stafleu van Loghum, 2006

Medewerker Pinkhof Geneeskundig woordenboek

The catechol-O-methyltransferase gene and schizophrenia.
Zinkstok J, van Amelsvoort T, De Haan L, Baas F, Linszen D.
Chapter in “Trends in Schizophrenia Research” edited by Mary V. Lang, pp. 45-78COMT gene and schizophrenia

Mijn eten is vergifitigd door de duivel
Dekker N, De Haan L
In: Probleemgeorienteerd denken in de Psychiatrie Van Balkom T, Hengeveld MW red
Pag 249- 256
De Tijdstroom, Utrecht, 2005

Sinds ik die pillen slik zijn mijn benen zo onrustig
Dekker N, De Haan L
In: Probleemgeorienteerd denken in de Psychiatrie Van Balkom T, Hengeveld MW red
Pag 315- 323
De Tijdstroom, Utrecht, 2005

Psychotische stoornissen
De Haan L, Kahn R
In: Leerboek Psychiatrie Hengeveld MW, Van Balkom T red
Pag 217- 232
De Tijdstroom, Utrecht, 2005

Cannabis abuse and the course of schizophrenia
Linszen DH, Peters B, De Haan L
Pag. 119-126
In: Marihuana and Madness. D. Castle, R. Murray, editors
Cambridge University Press
Cambridge, 200
Awarded the British Medical Association Mental Health Book of Year 1st prize

Subjectieve ervaring en antipsychotica
Pag 171- 183
De Haan L
In: Jaarboek voor psychiatrie en psychotherapie 2003-2004
Schene AH, Boer F, Heeren TJ, Henselmans HWJ, Sabbe B, Van Weeghel J (red)
Bohn Stafleu Van Loghum
Houten/Mechelen 2003

Co-operation in case of imminent relapse
De Haan L, Scholte WF
In: Community care and psychiatric rehabilitation
Van Weeghel J (red)
Sphere, Kiev Ukraine 2002

Psychose, informatie voor clienten, famlie en andere betrokkenen
Lid van de adviescommissie
Brochure Trimbos-instituut, Utrecht, 2002

Breaking the silence. Carers' views on the help given during the first episode of psychosis, a European perspective
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L
Publication of EUFAMI, Madrid, 2001 (The European Federation of Associations of people with a Mental Illness)

Die hilfsangebote bei einer ersten psychotischen episode aus der sicht der betreuende angehorigen. Eine Europaische studie.
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L

Anghorigas synpunkter pa den hjalp som givits vid forsta psykosepiod. Ett Europeiskt perspektiv
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L

El punto de vista delcuidador sobre la ayuda proporcionada en un primer episodio de psicosis. Una perspectiva Europea
De Haan L, Kramer L, van Raay B, Weir M, Gardner J, Akselson S, Ladinser E, McDaid S, Hernández Dols S, Wouters L

Patients’ perspectives, subjective experiences and attitudes of patients with recent onset schizophrenia
De Haan L
Thesis, University of Amsterdam, Amsterdam, 2001

Het belang van hospitalisatie bij een eerste psychotische episode
Pag 137-146
De Haan L
In: Schizofrene stoornissen
Peuskens J, De Clerq M (red)
Academia Press, Gent 1999

Antipsychotica
Pag 47-61
De Haan L
In: Gezinsbegeleiding bij psychotische patienten
Dingemans PMAJ, de Pater-Zijlstra MA (red.)
Bohn Stafleu Van Loghum, Houten/Diegem 1998

Brochure: Voor het eerst een psychose
De Haan L, Stavenuiter B, Stockmann M, Vlaminck P
38 pagina's
Ypsilon, 1998

Samenwerken bij dreigende terugval
Pag 203-211
De Haan L, Scholte WF
In: Onderzoek van Schizofrenie: implicaties voor de behandeling
Dingemans PMAJ, van der Bosch R, Kahn R, Schene AH (red)
Bohn Stafleu Van Loghum, Houten 1995

Other: Abstracts

Subjective Experience and Dopamine D2 Receptor Occupancy in Patients treated with Antipsychotics:
Clinical Implications
De Haan L
The International Journal of Neuropsychopharmacology, 2006, 9, sp76.05

Obsessive Compulsive Symptoms in a Randomized Double Blind Study with Olanzapine or Risperidone in Young
Patients with Recent-onset Schizophrenia or Related Disorders.
Van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van den Brink W, Linszen D
Schizophrenia Research, 2006, 69, 99-100

Subjective Well-being and Craving for Cannabis in First Psychosis, a Randomized Double Blind
Comparison of Olanzapine vs Risperidone
Van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van den Brink W, Linszen D
Schizophrenia Research, 2006, 69, 141

MATCH: The effect of motivational interviewing on adherence to antipsychotic treatment in schizophrenia
Barkhof E, Meijer CJ, De Haan L, De Sonneville LJM, Linszen D
Schizophrenia Research, 2006, 69, 100-101

The COMT gene and OCS in patients with recent onset schizophrenia
Baas F, Zinkstok J, Nimwegen L, Van Amelsvoort T, De Haan L, Linszen D.
Schizophrenia Research, 2006, 69, 188

A three year follw-up of OCD and OCS in 148 patients with a first episode of schizophrenia, schziophreniform
or schizoaffective disorder: aggression and substance abuse
De Haan L, Van Amelsvoort T, Dingemans P, Linszen D
Schizophrenia Research, 2006, 69, 232

Dopaminergic neurotransmission in 22Q11deletion syndrome before and after dopamine depletion
Boot E, Booij J, Zinkstok J, De Haan L, Linszen D, Abeling N, Van Amelsvoort T
Schizophrenia Research, 2006, 69, 271

Can long term critical period interventions in the early phase of schizophrenia like disorders prevent deterioration
Linszen D, De Haan L, Dingemans P, Wouters L
Schizophrenia Research, 2006, 69, 7

Opinions of mothers towards the first psychotic episode and the start of treatment of their child
De Haan L, Welborn K, Krikke M, Linszen D
Schizophrenia Research, 2004, 67, 33

Early and 3-year sustained intervention in first episode schizophrenia: relapse, stabilization and its predictors
Linszen DH, Wouters L, Dingemans PMAJ, De Haan L, Nieman D
Schizophrenia Research, 2004, 67, 18

Confirmatory factor analysis of the positive and negative symptom scale
Van der Gaag M, Cuijpers A, Wiersma D, De Haan L, Hijman R, Van Harten P, Van Meijel B, De Hert M, Arends J
Schizophrenia Research, 2004, 67, 72-73

Subjective reasons for cannabis use and prodromal symptoms in recent-onset schizophrenia and in a general population
Peters BD, De Koning PP, De Haan L, Linszen DH
Schizophrenia Research, 2004, 67, 219

Reduced white matter integrity in recent-onset schizophrenia as assessed with diffusion tensor imaging
Peters BD, Vlieger E, De Haan L, Majoie CB, Den Heeten GJ, Linszen DH
Schizophrenia Research, 2003, 204-205

Treatment reluctance in first episode schizophrenia: Lack of insight, non-compliance and cannabis abuse predict bad outcome after eighteen months intervention
Linszen DH, De Haan L, Dingemans P, Van Bruggen M, Hofstra N, Van Engelsdorp H, Ter Smitten M
Schizophrenia Research, 2003, 325

Psychometric properties of the Subjective Well-being under Neuroleptics scale (SWN) and the Subjective Deficit Syndrome Scale (SDSS)
De Haan L, Weisfelt M, Dingemans PMAJ, Linszen DH, Wouters L
Schizophrenia Research, 2001, 49: 282

Obsessions in pa¬tients with schi¬zophrenia during treatment with clozapine
De Haan L, Linszen DH, Gorsira R
Psychosis and Schizophrenia, 2001, 1, 9 (extended abstract)

How is optimal dosage to be determined? Subjective experience and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized on olanzapine or risperidone
De Haan L, Lavalaye J, Linszen DH, Dingemans PMAJ, Booij J
Schizophrenia Research, 2000, 41: 26 (oral presentation at the Biennal Winterworkshop on schizophrenia in Davos)

Attitudes of patients concerning the first psychotic episode and the start of treatment
De Haan L, Peters B, Dingemans PMAJ, Wouters L, Linszen DH
Schizophrenia Research, 2000, 41: 227

Obsessive-Compulsive Symptoms during treatment with olanzapine and risperidone, indication of differences in the long-term. Preliminary results from a prospective study
De Haan L, Beuk N, Linszen DH, Dingemans PMAJ
Schizophrenia Research, 2000, 41: 191

Early intervention and the course of recent onset schizophrenia
Linszen DH, Dingemans PMAJ, Lenior ME, De Haan L, Scholte WF
European Psychiatry, 1998, S12
 

Prof. PhD L. de Haan (Recent onset schizophrenia)

Psychosis, Variation, Phase, Profile

Needs, circum¬stances and characteristics of people with psychotic disorders differ substantially. In research we need to capture this variation in phase and profile.
We focus on patients with recent onset psychotic disorders and their variation - in therapeutic and subjective response on antipsychotic treatment, - co-morbidity and - cognitive and social functioning.
These variations are thought to be partly related to differences in dopaminergic neurotransmission.
Increased striatal dopamine synthesis and dopamine reactivity to stress is related to dysregulated salience attribution and thereby psychotic symptoms. Modulation of dopaminergic neurotransmission by antipsychotic medication and illicit drugs affects symptoms and wellbeing.

The three main strategic research objectives of the Early Psychosis Department are:
1. Finding brain and behavioral characteristics of specific disturbances in early psychotic disorders.
a. Identify the relationship between neural activity and specific disturbances in psychotic disorders.
b. Identify genetic and environmental factors associated with variation in early psychotic disorders.
c. Identify biological markers in patients with psychotic disorders.
2. Define the developmental trajectories around onset of psychotic disorders to determine when and how to intervene.
3. Develop better interventions directed at the diverse needs, circum¬stances and characteristics of people with early psychotic disorders.
 

Postdocs
MD PhD N. Dekker
MD PhD R.M.C. Klaassen
PhD N. Korver
MD PhD M.W.J. Machielsen
MD PhD P.D. Meesters
PhD C.J. Meijer
MD PhD J.H. Meijer
PhD D.H. Nieman
MD PhD B.D. Peters
MD PhD N.J.M. van Beveren
MD PhD L.J.M. van Nimwegen
PhD M.J. van Tricht
MSc PhD E. Velthorst

• H.E. Becker
• S. Berendsen
• T.J. Burger
• N. Cakici
• P. Doedens
• J.M. Hagen
• K.L. Helmus
• S. Medema
• F.L. Oosterwijk
• A.L. Sutterland
• A.M. Tedja
• H.S. van der Heijden
• M. van der Pluijm
• R.M. van Eck

• AMC